Welcome to our dedicated page for Donaldson news (Ticker: DCI), a resource for investors and traders seeking the latest updates and insights on Donaldson stock.
Donaldson Company, Inc. (NYSE: DCI) is a global manufacturer of technology-led filtration products and solutions, with operations organized into Mobile Solutions, Industrial Solutions and Life Sciences segments. This news page aggregates coverage related to Donaldson’s business performance, corporate actions and participation in key industrial and life sciences events.
Investors and industry followers can use this page to review earnings announcements, such as Donaldson’s reports of record quarterly and full-year sales and earnings, and updates on segment performance across Mobile, Industrial and Life Sciences. Company releases discuss factors like pricing, volume, foreign currency translation, tariff impacts, cost optimization initiatives and guidance for sales, operating margin and earnings.
News items also include capital allocation and dividend updates. Donaldson reports on quarterly cash dividend declarations and notes its membership in the S&P High-Yield Dividend Aristocrats Index, with a long record of consecutive annual dividend increases and quarterly dividend payments. Disclosures on share repurchases and cash flow provide additional context on how the company returns capital to shareholders while funding investments in its operations.
Corporate governance and investor relations activities are another focus of Donaldson’s news. Releases cover the annual meeting of stockholders, director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. The company also announces participation in investor conferences and webcasts of its earnings conference calls, giving insight into how management communicates with the market.
In addition, Donaldson-related news can highlight developments in its Life Sciences segment, including the role of Isolere Bio by Donaldson in biopharmaceutical purification technologies and collaborations where Isolere Bio participates as a partner. Readers who follow DCI news can track how the company positions its filtration technologies across mobile, industrial and life sciences markets over time.
Donaldson Company (NYSE:DCI) has formed a strategic partnership with Mighty Distributing System of America to expand its heavy-duty filtration solutions distribution. The collaboration combines Donaldson's OE-grade filtration expertise with Mighty's inventory management services, targeting HD fleet facilities, diesel repair centers, and off-highway operations.
The partnership aims to serve a market of over 15 million Class 7 and 8 trucks in the U.S., with the heavy-duty parts aftermarket projected to reach $92.7 billion in 2025. Mighty will provide localized inventory support and premium Donaldson filtration products, including air, oil, fuel, and hydraulic filters, helping facilities reduce surplus stock and improve equipment uptime.
Donaldson Company (NYSE:DCI) celebrated its 2024 patent recipients and Inventor Award winners, recognizing over 100 employees for their contributions to innovation. The company registered 392 new patents in 2024 and currently holds 3,260 active U.S. and international patents. The ceremony honored inventors in five categories: Emerging Innovator, Manufacturing Excellence, Technology Champion, Technology Achievement, and Frank A. Donaldson Award.
Notable winners included Mikayla Yoder for oleophobic materials research, Jon Haag for virtual production line installation, Gert Willems for Clean Seal technology development, Vincent Kayaerts for thermoplastic elastomer seal products, and Dan Tuma for disk drive filtration technology advancements.
Univercells Technologies, a Donaldson Life Sciences business, has launched the scale-X™ nitro controller, expanding its fixed-bed bioreactor portfolio. The new controller operates both 200 and 600 m² scale-X nitro bioreactors, enabling rapid scalability from R&D to commercial production in just 8 months.
The compact system features a 1.6 m² footprint, supports both adherent and suspension cell cultures, and can reduce production costs by 36% to 82% compared to other adherent methods. It's designed for viral vaccines, exosomes, LV and AAV vector production, oncolytic viruses, and recombinant proteins manufacturing. Pre-orders will open in June 2025, with shipments starting in early 2026.
Donaldson Company (NYSE: DCI), a global filtration technology leader, has scheduled its third quarter fiscal 2025 earnings conference call for Tuesday, June 3, 2025, at 9:00 a.m. CT. The live webcast will be accessible through the "Events & Presentations" section of Donaldson's Investor Relations website at IR.Donaldson.com. A replay will be available from approximately 12:00 p.m. CT on the same day.
Founded in 1915, Donaldson operates through three primary segments: Mobile Solutions, Industrial Solutions, and Life Sciences, serving diverse industries and advanced markets across six continents with over 140 locations worldwide.
Donaldson Company (NYSE: DCI), a global filtration technology leader, announced that CFO Brad Pogalz will present at the Oppenheimer 20th Annual Industrial Growth Conference on May 5, 2025, at 11:15 a.m. ET. The presentation will be available via live webcast through Donaldson's Investor Relations website, with replay access for approximately 90 days following the event.
Founded in 1915, Donaldson operates through three primary segments: Mobile Solutions, Industrial Solutions, and Life Sciences. The company maintains a presence in over 140 locations across six continents, serving diverse industries from small businesses to major OEM brands.
Isolere Bio by Donaldson has announced the availability of its manufacturing-grade IsoTag™ AAV reagent for purifying Adeno-associated Virus (AAV) vectors. The product now includes validated processes and comprehensive documentation, including a Regulatory Support File and FDA-acknowledged Drug Master File (DMF).
The technology, based on liquid-liquid phase separation developed at Duke University's Chilkoti Lab, combines affinity- and size-based separations using a recombinant protein. The company began select collaborations in 2021, made the product commercially available in 2023, and released the research-grade version in October 2024.
This advancement aims to address bottlenecks in GMP manufacturing and streamline purification processes for AAV-based gene therapies. The company will showcase the technology at ASGCT in New Orleans from May 13-17, featuring presentations on neutral pH elution of AAV and liquid-phase affinity purification technologies.